Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 14, Issue 2, 2004, Pages 135-142

  Hiraga, Yoshiko ^a   Yuhki, Yoshimitsu ^a   Itoh, Katsumi ^a   Tadano, Kohji ^a   Takahashi, Yasushi ^a   Mukai, Masaya ^a  

^a SAPPORO CITY GENERAL HOSPITAL   (Japan)

Author keywords

Methotrexate (MTX); Pharmacokinetics; Rheumatoid arthritis (RA)

Indexed keywords

C REACTIVE PROTEIN; FOLIC ACID; METHOTREXATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 20444389821     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-004-0280-y     Document Type: Article

References (30)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
2. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
3. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
4. Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis (in Japanese). Ensho 1996;16:437-58.
5. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:411-59.
6. Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
7. Bressolle F, Bologna C, Edno L, Bernard JC, Gomeni R, Sany J, et al. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 1996;49:285-92.
8. Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, et al. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis. Int J Clin Pharmacol Ther 1998;36:227-30.
9. Suzuki T, Suzuki Y, Matsuyama T, Ohhashi H, Hashimoto H. Pharmacokinetics after an intermittent low-dose methotrexate treatment in patients with rheumatoid arthritis (in Japanese). Jpn J TDM 1998;4:340-5.
10. Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS Jr. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1989;16:745-8.
11. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844-9.
12. Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475-7.
13. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.
14. Seideman P. Methotrexate - the relationship between dose and clinical effect. Br J Rheumatol 1993;32:751-3.
15. Totokawa S, Furuya T, Nakajima A, Suzuki T, Kashiwazaki S. Effects of low-dose methotrexate therapy in rheumatoid arthritis: A comparison of three different dosage regimens (in Japanese). Ryumachi 1997;37:681-7.
16. Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993;20: 1573-7.
17. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:677-81.
18. Yamaoka K, Tanigawara Y. MULTI 2 (BAYES) (in Japanese). In: Hori R, editor. Population pharmacokinetics nyuumonn (Primer of population pharmacokinetics). 1st ed. Tokyo: Yakugyojihosya; 1988. p. 103-31.
19. Bressolle F, Kinowski JM, Morel J, Pouly B, Sany J, Combe B. Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol 2000;27:2110-4.
20. Yasuda H. Age-related change in renal function. Differences between the Japanese and the Caucasians in a nomogram and a formula for evaluation of glomerular filtration rate (in Japanese). Med Biol 1980;101:83-6.
21. Sueyasu M, Mishima K, Shuto H, Hirakawa M, Kataoka Y, Oishi R, et al. Population pharmacokinetic parameters of high-dose methotrexate in osteogenic sarcoma (in Japanese). Jpn J TDM 1997;1:85-6.
22. Luyckx M, Cazin JL, Burnet C, Gosselin P, Demaille MC. Clinical pharmacokinetics of a 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. Eur J Clin Pharmacol 1985;28:457-62.
23. Bokkerink JP, Bakker MA, Hulscher TW, De Abreu RR, Schretlen ED, van Laarhoven JP, et al. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 1986;35: 3549-55.
24. Bokkerink JP, De Abreu RA, Bakker MA, Hulscher TW, van Baal JM, Schretlen ED, et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988;37:2329-38.
25. Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-50.
26. Fujimoto T. Methotrexate with leucovorin rescue (in Japanese). Igaku no Ayumi 1998;184:440-3.
27. Takeuchi A, Masuda S, Saito H, Hashimoto Y, Inui K. Transstimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1. J Pharmacol Exp Ther 2000;293:1034-9.
28. Horne DW, Reed KA. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001;394:39-44.
29. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
30. Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-63.